Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice-论文-万方医学网

首页> > Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice

Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice

导出原文传递

翻译打印收藏纠错

第一作者： Ciolek, Alana M.

作者： Ciolek, Alana M. ^[1] ; Arnall, Justin ^[2] ; Moore, Donald C. ^[3] ; Palkimas, Surabhi ^[4] ; Der-Nigoghossian, Julie ^[5] ; Dane, Kathryn ^[6]

作者单位： Irving Med Ctr,Columbia Univ ^[1] Atrium Hlth ^[2] Atrium Hlth,Levine Canc Inst ^[3] Univ Colorado Hosp ^[4] Pratt Inst ^[5] Johns Hopkins Univ Hosp ^[6]

关键词 recombinant factor VII SEVENFACT NovoSeven FEIBA hemophilia bypassing agent inhibitors FACTOR-VII NOVOSEVEN(R)RECOMBINANT FACTOR VIIA BYPASSING AGENTS THROMBOSIS ARYOSEVEN

发布时间 2022-08-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice

相似文献

同项目论文

相关期刊

检索历史 清除

Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice

相似文献

同项目论文

相关期刊

检索历史清除